Get started
Work

A phase 2 clinical trial of adjuvant ado-trastuzumab emtansine (T-DM1) for patients with HER2-positive salivary gland cancer.

Year: 2025
Type: article
DOI: 10.1200/jco.2025.43.16_suppl.tps6124
Authors: Glenn J. Hanna, Ruichao Shi, Jay Justin Liao, Alexander T. Pearson, Ari Joseph Rosenberg, Alan Loh Ho, Eleni M. Rettig, Roy B. Tishler, Rosh K. Sethi, Donald J. Annino, Laura A Goguen, Kartik Sehgal, Michael J. Dennis, Vickie Y. Jo, Kristine S. Wong, Conor Ernst Steuer, Ravindra Uppaluri, Jonathan Daniel Schoenfeld, Robert I. Haddad, Danielle N Margalit
Institutions: Dana-Farber Cancer Institute, University of Washington Medical Center, University of Chicago, Memorial Sloan Kettering Cancer Center, Dana-Farber Brigham Cancer Center, Brigham and Women's Hospital, Emory University, Harvard University
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: closed
OpenAlex ID: W4410810956
FWCI:
Cites:
Cited by:
Related to: 10